Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo

Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods Serum samples were collected in a cohort...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-09, Vol.18 (9), p.e0286479-e0286479
Main Authors: Zola Matuvanga, Trésor, Mariën, Joachim, Larivière, Ynke, Osang'ir, Bernard Isekah, Milolo, Solange, Meta, Rachel, Esanga, Emmanuel, Maketa, Vivi, Matangila, Junior, Mitashi, Patrick, Ahuka Mundeke, Steve, Muhindo-Mavoko, Hypolite, Muyembe Tamfum, Jean-Jacques, Van Damme, Pierre, Van Geertruyden, Jean-Pierre
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Assaying
Biology and life sciences
Care and treatment
Congo (Kinshasa)
Control
Diagnosis
Ebola virus
Ebola virus infections
Ebolavirus
Enzyme-linked immunosorbent assay
Epidemics
Evaluation
Health care
Hospitals
Medicine and Health Sciences
People and Places
Public health administration
Research and Analysis Methods
Serology
Testing laboratories
Vaccines
Viral diseases
Viruses
VP40 protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7-2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0-1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5-10.9) samples using FANG ELISA. Conclusion In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0286479